MIRUM PHARMACEUTICALS, INC.

(MIRM)
  Report
Delayed Nasdaq  -  05/23 04:00:00 pm EDT
25.23 USD   -1.37%
05/23Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals in Cash-and-Stock Deal; Shares Drop
MT
05/23HC Wainwright Adjusts Price Target for Mirum Pharmaceuticals to $69 From $64, Maintains Buy Rating
MT
05/23MIRUM PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about MIRUM PHARMACEUTICALS, INC.
05/23Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals in Cash-and-Stock Deal; Shares ..
MT
05/23HC Wainwright Adjusts Price Target for Mirum Pharmaceuticals to $69 From $64, Maintains..
MT
05/23Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals
BU
05/18Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
05/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
05/05TRANSCRIPT : Mirum Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
05/05Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Busines..
BU
05/05Mirum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/05Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Reports Q1 Revenue $12.9M, vs. Street Est o..
MT
05/02Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Confere..
BU
04/26SVB Leerink Adjusts Mirum Pharmaceuticals' Price Target to $49 from $46, Keeps Outperfo..
MT
04/08Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
03/29CANbridge Pharmaceuticals Inc. and Mirum Pharmaceuticals Sign an Exclusive License Agre..
CI
03/11Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
03/11Raymond James Adjusts Mirum Pharmaceuticals' Price Target to $74 From $70, Keeps Strong..
MT
03/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
03/09TRANSCRIPT : Mirum Pharmaceuticals, Inc., Q4 2021 Earnings Call, Mar 09, 2022
CI
03/09Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 3..
CI
03/09MIRUM PHARMACEUTICALS : Reports Fourth Quarter and Year-End 2021 Financial Results and Pro..
PU
03/09Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended Decem..
CI
03/09Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Reports Q4 Revenue $3.1M
MT
03/09Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Pr..
BU
03/02Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021..
BU
02/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
02/09Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conferenc..
BU
01/28SVB Leerink Adjusts Mirum Pharmaceuticals' Price Target to $46 from $42, Keeps Outperfo..
MT
01/19CANbridge Pharmaceuticals CAN108 New Drug Application (NDA), for Alagille Syndrome, Acc..
AQ
01/12Raymond James Adjusts Mirum Pharmaceuticals Price Target to $70 From $69, Maintains Str..
MT
01/11TRANSCRIPT : Mirum Pharmaceuticals, Inc. Presents at JPMorgan 40th Annual Healthcare Confe..
CI
01/11Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
01/11MIRUM PHARMACEUTICALS : Provides Business Update and Highlights Key 2022 Corporate Milesto..
PU
01/11Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milest..
BU
01/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
01/04Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference o..
BU
01/03Immix Biopharma Shares More Than Double on FDA Designation
DJ
01/03Immix Biopharma Shares Soar Premarket After Key FDA Designation
DJ
2021MIRUM PHARMACEUTICALS : Completion of Acquisition or Disposition of Assets - Form 8-K
PU
2021MIRUM PHARMACEUTICALS, INC.(NASDAQGM : MIRM) added to NASDAQ Biotechnology Index
CI
2021Mirum Pharmaceuticals to be Added to Nasdaq Biotechnology Index
MT
2021Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index
BU
2021LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in A..
BU
2021LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in A..
CI
2021Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 202..
BU
2021INSIDER BUY : Mirum Pharmaceuticals
MT
2021Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
2021Longeveron Shares Soar 120% on Key FDA Designation
DJ
2021Mirum to Sell Livmarli Priority Review Voucher for $110 Million
MT
2021Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher
BU
2021TRANSCRIPT : Mirum Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 15, 2021
CI
2021MIRUM PHARMACEUTICALS : Reports Third Quarter 2021 Financial Results and Provides Business..
PU
2021Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
2021Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Busines..
BU
2021Six-Year Natural History Comparison with Mirum's LIVMARLI (maralixibat) Demonstrates Ev..
BU
2021Mirum Pharmaceuticals, Inc. Announces That A New Analysis Comparing Pooled Livmarli? (M..
CI
2021Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conferenc..
BU
2021Mirum Pharmaceuticals to Present Maralixibat Data at Scientific Conference
MT
2021New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021
BU
2021The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixib..
BU
2021The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixib..
CI
2021MIRUM PHARMACEUTICALS : HC Wainwright Raises Price Target for Mirum Pharmaceuticals to $64..
MT
2021MIRUM PHARMACEUTICALS : Baird Adjusts Mirum Pharmaceuticals PT to $34 From $30, Maintains ..
MT
2021MIRUM PHARMACEUTICALS : SVB Leerink Adjusts Price Target on Mirum Pharmaceuticals to $41 F..
MT
2021MIRUM PHARMACEUTICALS : Raymond James Adjusts Mirum Pharmaceuticals PT to $69 from $51, Ma..
MT
2021MIRUM PHARMACEUTICALS : U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only App..
PU
2021TRANSCRIPT : Mirum Pharmaceuticals, Inc. - Special Call
CI
2021MIRUM PHARMACEUTICALS : Gets FDA's OK for Livmarli Oral Solution to Treat Chronic Itch in ..
MT
2021MIRUM PHARMACEUTICALS : oral drug becomes first U.S. approved Alagille syndrome therapy
RE
2021MIRUM PHARMACEUTICALS : FDA approves Mirum Pharma's drug for itching associated with rare ..
RE
2021MIRUM PHARMACEUTICALS : U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only App..
BU
2021Mirum Pharmaceuticals, Inc Receives U.S. Food and Drug Administration Approval LIVMARLI..
CI
2021MIRUM PHARMACEUTICALS : Halted on Pending News; Shares Up 3% in Recent Trading
MT
2021MIRUM PHARMA : FDA OKs Livmarli to Treat Cholestatic Pruritus in Certain Patients
DJ
2021MIRUM PHARMACEUTICALS : Partners With Takeda Over Developing, Commercializing Liver Diseas..
MT
2021Mirum Inks Japan License for Maralixibat With Takeda
DJ
2021MIRUM PHARMACEUTICALS : JPMorgan Starts Mirum Pharmaceuticals at Overweight with $30 PT
MT
1  2  3  4Next
Upcoming event on MIRUM PHARMACEUTICALS, INC.